Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging double-blind, placebo-controlled phase 2 study of tezepelumab with or without topical corticosteroids in moderate-to-severe atopic dermatitis
2018-001997-52Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tezepelumab in atopic dermatitis (AD) (4 arms), sponsored by Amgen. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-001997-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001997-52.